<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479852</url>
  </required_header>
  <id_info>
    <org_study_id>SP-624-201</org_study_id>
    <nct_id>NCT04479852</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirtsei Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirtsei Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as&#xD;
      compared to placebo in the treatment of adults with Major Depressive Disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) total score</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The Montgomery Asberg Depression rating scale is a 10-item scale used to assess the severity of depression. Individual items are scored on a 7-point scale (0 to 6). The total score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Weeks 1, 2, and 3 in Montgomery Asberg Depression Rating Scale total score</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>The Montgomery Asberg Depression rating scale is a 10-item scale used to assess the severity of depression. Individual items are scored on a 7-point scale (0 to 6). The total score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Weeks 1, 2, 3, and 4 in Clinical Global Impression - Severity (CGI-S) total score</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The CGI-S is a 7-point scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. A score of 1 represents &quot;normal&quot; and 7 represents &quot;most extremely ill&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 5 and change from Week 4 to Week 5 in MADRS total score</measure>
    <time_frame>Up to 5 weeks</time_frame>
    <description>The Montgomery Asberg Depression rating scale is a 10-item scale used to assess the severity of depression. Individual items are scored on a 7-point scale (0 to 6). The total score is the sum of individual items, ranging from 0 to 60; where a higher score indicates more depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 5 and change from Week 4 to Week 5 in CGI-S total score</measure>
    <time_frame>Up to 5 weeks</time_frame>
    <description>The CGI-S is a 7-point scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. A score of 1 represents &quot;normal&quot; and 7 represents &quot;most extremely ill&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 2 and Week 4 in the 17-item Hamilton Depression Rating Scale (HAM D-17) total score</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The 17-item Hamilton Depression rating scale is used to assess the severity of depression. Individual items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4), with 0=No difficulty/absent and 4=most severe. The total score is the sum of individual items, ranging from 0 to 52; where a higher score indicates more depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 2 and Week 4 in the Sheehan Disability Scale (SDS)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The Sheehan Disability Scale is a 3-part scale that measures the degree of disruption on work, social and family life using an 11-point scale where 0 represents &quot;no disruption&quot; and 10 represents &quot;extreme disruption&quot;. In addition to the 11-point scale, participants are asked to indicate the number of days in the past week that were &quot;lost&quot; and numbers of days that were &quot;unproductive&quot;. The results of these questions have a range from 0 to 7. A total global functioning impairment score can be utilized by summing the scores from work, social and family life scales for a value range from 0 to 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 2 and Week 4 in the Quick Inventory of Depressive Symptomology - Self Report (QIDS-SR)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The Quick Inventory of Depressive Symptomology - Self Report (QIDS-SR), is a 16 item self-reported scale where each item has a 4-point scale where 0 represents least impact scores while 3 represents greatest impact scores. Some questions are linked. The total score ranges from 0 to 27 where a higher score indicates more depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 2 and Week 4 in the Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 16 item satisfaction scale where each item has a 5-point scale. A score of 1 represents &quot;very poor satisfaction&quot;, while a score of 5 represents &quot;very good satisfaction&quot;. Only the first 14 items are summed for a total score that ranges from 14 to 70.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>SP-624</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral capsule, 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-624</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>SP-624</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent to participate in the study&#xD;
&#xD;
          -  Males and females, aged 18 to 65 years&#xD;
&#xD;
          -  In generally good physical health&#xD;
&#xD;
          -  Body mass index (BMI) must be between 18 and 40 kg/m2&#xD;
&#xD;
          -  Females of reproductive potential and males with partners of reproductive potential&#xD;
             must agree to remain abstinent or use adequate and reliable contraception throughout&#xD;
             the study and for at least 30 days after the last dose of study drug&#xD;
&#xD;
          -  Subjects must meet criteria for moderate to severe Major Depressive Disorder, as&#xD;
             confirmed by the Mini International Neuropsychiatric Interview (MINI)&#xD;
&#xD;
          -  Willing and able to comply with the study design schedule and other requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female who is pregnant, breastfeeding, or less than six months postpartum at Screening&#xD;
&#xD;
          -  History or presence of any clinically significant medical condition, disease, or&#xD;
             surgical history that could jeopardize the safety of the subject or validity of the&#xD;
             study data, or interfere with the absorption, distribution, metabolism, or excretion&#xD;
             of the study drug&#xD;
&#xD;
          -  Failure to discontinue all psychoactive medications or psychoactive supplements&#xD;
             including antidepressants and mood stabilizers, within a time period prior to Baseline&#xD;
             corresponding to at least five half-lives of the medication in question&#xD;
&#xD;
          -  Presence of a clinically significant abnormality on physical examination or&#xD;
             electrocardiogram (ECG), including a corrected QT interval using Fridericia's formula&#xD;
             (QTcF) &gt;450 msec for males and &gt;470 msec for females&#xD;
&#xD;
          -  Presence of uncontrolled hypertension, defined as consistent systolic blood pressure&#xD;
             (SBP) &gt;160 mmHg or consistent diastolic blood pressure (DBP) &gt;95 mmHg despite present&#xD;
             therapy&#xD;
&#xD;
          -  Screening laboratory value(s) outside the laboratory reference range that are&#xD;
             considered to be clinically significant by the Investigator (clinical chemistry,&#xD;
             hematology, coagulation, and urinalysis)&#xD;
&#xD;
          -  Screening liver function tests (ALT, AST, Alkaline phosphatase) &gt; 2x the upper limit&#xD;
             of normal&#xD;
&#xD;
          -  Subjects who, in the opinion of the Investigator, are not suitable candidates for the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Rigdon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sirtsei Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuki Prescott</last_name>
    <phone>919-460-9500</phone>
    <phone_ext>2008</phone_ext>
    <email>yprescott@quatrobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alea Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Goewey</last_name>
      <email>AGoewey@Alearesearchphoenix.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Poole</last_name>
      <email>APoole@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Powell</last_name>
      <email>rpowell@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>866-267-8742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Nunez</last_name>
      <email>mdnunez@artemis-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rey Levi Calisin</last_name>
      <email>Reylevicalisin@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Martinez</last_name>
      <email>Sally@ehsfamily.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Gellers</last_name>
      <email>bgellers@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fedor Richani</last_name>
      <email>frichani@segaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Littlejohn</last_name>
      <email>blittlejohn@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn McArthur</last_name>
      <email>kmcarthur@acmr.org</email>
    </contact>
    <contact_backup>
      <last_name>Grace Kalala</last_name>
      <email>gkalala@acmr.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>American Medical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manaal Pandit</last_name>
      <email>mpandit@americanmedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CBH Health</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Coyle</last_name>
      <email>dcoyle@cbhhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Research Group</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Meyer</last_name>
      <email>jmeyer@midwestresearchgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Jensen</last_name>
      <email>jjensen@altearesearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolph McClain</last_name>
      <email>rmcclain@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayon Choe</last_name>
      <email>kchoe@cfef.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Ogg</last_name>
      <email>aogg@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Gutkin</last_name>
      <email>jgutkin@spristudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manhattan Behavioral Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Escobar</last_name>
      <email>Escobar@nymbm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristianna Maldonado</last_name>
      <email>kgennaro@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richard H. Weisler, MD, PA &amp; Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ellis</last_name>
      <email>mellis@ErgClinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristie Harzman</last_name>
      <email>kharzman@cuttingedgeresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Lehigh Center for Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Tesche</last_name>
      <email>ntesche@lehighcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Iskiwitz</last_name>
      <email>kiskiwitz@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Donald J. Garcia, Jr., MD, PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78737</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Huebner</last_name>
      <email>mhuebner@pppatx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Future Search Trials of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Ashmore</last_name>
      <email>erina@fstrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Sadeghi</last_name>
      <email>ropa49@earthlink.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core Clinical Research</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Golescu</last_name>
      <email>maria.golescu@ccrtrial.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

